IMA Wealth Inc. Has $1.98 Million Stake in Intuitive Surgical, Inc. (NASDAQ:ISRG)

IMA Wealth Inc. decreased its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 4.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 5,881 shares of the medical equipment provider’s stock after selling 299 shares during the quarter. IMA Wealth Inc.’s holdings in Intuitive Surgical were worth $1,984,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. Baystate Wealth Management LLC lifted its stake in Intuitive Surgical by 150.0% in the fourth quarter. Baystate Wealth Management LLC now owns 75 shares of the medical equipment provider’s stock valued at $25,000 after buying an additional 45 shares during the period. MCF Advisors LLC lifted its stake in Intuitive Surgical by 108.1% in the fourth quarter. MCF Advisors LLC now owns 77 shares of the medical equipment provider’s stock valued at $26,000 after buying an additional 40 shares during the period. Atticus Wealth Management LLC lifted its stake in Intuitive Surgical by 85.4% in the fourth quarter. Atticus Wealth Management LLC now owns 89 shares of the medical equipment provider’s stock valued at $30,000 after buying an additional 41 shares during the period. OFI Invest Asset Management acquired a new position in Intuitive Surgical in the third quarter valued at about $25,000. Finally, Headinvest LLC acquired a new position in Intuitive Surgical in the third quarter valued at about $28,000. Institutional investors and hedge funds own 83.64% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on ISRG shares. Robert W. Baird dropped their price target on Intuitive Surgical from $440.00 to $436.00 and set an “outperform” rating on the stock in a research report on Friday, April 19th. Truist Financial raised their price target on Intuitive Surgical from $390.00 to $435.00 and gave the stock a “buy” rating in a research report on Wednesday, January 24th. Piper Sandler raised their price target on Intuitive Surgical from $425.00 to $435.00 and gave the stock an “overweight” rating in a research report on Friday, April 19th. Royal Bank of Canada raised their price target on Intuitive Surgical from $400.00 to $432.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 24th. Finally, Raymond James raised their price target on Intuitive Surgical from $372.00 to $435.00 and gave the stock an “outperform” rating in a research report on Thursday, January 25th. Five analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. Based on data from MarketBeat, Intuitive Surgical presently has an average rating of “Moderate Buy” and an average target price of $396.17.

Insider Transactions at Intuitive Surgical

In other news, EVP Myriam Curet sold 5,318 shares of Intuitive Surgical stock in a transaction that occurred on Tuesday, April 23rd. The stock was sold at an average price of $370.66, for a total transaction of $1,971,169.88. Following the completion of the transaction, the executive vice president now directly owns 298 shares in the company, valued at approximately $110,456.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, EVP Myriam Curet sold 5,318 shares of Intuitive Surgical stock in a transaction that occurred on Tuesday, April 23rd. The stock was sold at an average price of $370.66, for a total transaction of $1,971,169.88. Following the completion of the transaction, the executive vice president now directly owns 298 shares in the company, valued at approximately $110,456.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Gary S. Guthart sold 24,325 shares of Intuitive Surgical stock in a transaction that occurred on Monday, January 29th. The stock was sold at an average price of $376.06, for a total value of $9,147,659.50. Following the transaction, the chief executive officer now owns 9,425 shares of the company’s stock, valued at $3,544,365.50. The disclosure for this sale can be found here. In the last three months, insiders sold 249,418 shares of company stock worth $96,300,959. 0.90% of the stock is owned by company insiders.

Intuitive Surgical Price Performance

ISRG stock traded up $2.21 during mid-day trading on Friday, reaching $375.33. The company had a trading volume of 927,845 shares, compared to its average volume of 1,564,565. The stock has a 50 day simple moving average of $386.19 and a two-hundred day simple moving average of $345.95. The company has a market capitalization of $133.13 billion, a price-to-earnings ratio of 67.75, a PEG ratio of 4.82 and a beta of 1.36. Intuitive Surgical, Inc. has a 52 week low of $254.85 and a 52 week high of $403.76.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share for the quarter, beating analysts’ consensus estimates of $1.40 by $0.10. The firm had revenue of $1.89 billion during the quarter, compared to the consensus estimate of $1.87 billion. Intuitive Surgical had a return on equity of 12.91% and a net margin of 27.16%. The business’s revenue was up 11.5% compared to the same quarter last year. During the same period last year, the company earned $1.00 earnings per share. On average, equities analysts predict that Intuitive Surgical, Inc. will post 4.8 EPS for the current year.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.